Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to 1.1%.

  • Pharma's Return on Capital Employed rose 1100.0% to 1.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.1%, marking a year-over-year increase of 1100.0%. This contributed to the annual value of 1.05% for FY2025, which is 1800.0% down from last year.
  • Per Pharma's latest filing, its Return on Capital Employed stood at 1.1% for Q3 2025, which was up 1100.0% from 1.05% recorded in Q2 2025.
  • Pharma's 5-year Return on Capital Employed high stood at 0.27% for Q2 2021, and its period low was 1.3% during Q2 2024.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.77% (2023), whereas its average is 0.81%.
  • In the last 5 years, Pharma's Return on Capital Employed crashed by -5300bps in 2024 and then skyrocketed by 2500bps in 2025.
  • Pharma's Return on Capital Employed (Quarter) stood at 0.37% in 2021, then tumbled by -91bps to 0.72% in 2022, then tumbled by -36bps to 0.98% in 2023, then fell by -19bps to 1.16% in 2024, then grew by 5bps to 1.1% in 2025.
  • Its Return on Capital Employed stands at 1.1% for Q3 2025, versus 1.05% for Q2 2025 and 1.12% for Q1 2025.